DSS
MCID: DNG001
MIFTS: 43

Dengue Shock Syndrome (DSS) malady

Categories: Infectious diseases, Skin diseases

Aliases & Classifications for Dengue Shock Syndrome

Aliases & Descriptions for Dengue Shock Syndrome:

Name: Dengue Shock Syndrome 12 52 14 69
Dss 12

Classifications:



External Ids:

Disease Ontology 12 DOID:0050125

Summaries for Dengue Shock Syndrome

Disease Ontology : 12 A dengue disease that involves the most severe form of dengue fever, has material basis in Dengue virus [NCBITaxon:12637] with four serotypes (Dengue virus 1, 2, 3 and 4), which are transmitted_by Aedes mosquito bite. The infection has symptom easy bruising, has symptom blood spots, has symptom bleeding gums, and has symptom nosebleeds. It is accompanied by circulatory collapse, involves hypotension, narrow pulse pressure (less than or equal to 20mm Hg), or frank shock. The shock occurs after two to six days of symptoms, followed by collapse, weak pulse, and blueness around the mouth.

MalaCards based summary : Dengue Shock Syndrome, also known as dss, is related to dengue disease and hepatitis, and has symptoms including easy bruising, blood spots and bleeding gums. An important gene associated with Dengue Shock Syndrome is THBD (Thrombomodulin), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Toll-Like receptor Signaling Pathways. The drugs Histamine and Ketotifen have been mentioned in the context of this disorder. Affiliated tissues include skin, heart and liver.

Related Diseases for Dengue Shock Syndrome

Diseases related to Dengue Shock Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 190)
id Related Disease Score Top Affiliating Genes
1 dengue disease 32.6 IL1B IL6 TNF
2 hepatitis 29.1 HLA-A HLA-DRB1 IL6 TNF
3 neuropathy, congenital hypomyelinating 11.0
4 dengue fever, protection against 11.0
5 dejerine-sottas disease 11.0
6 46xy sex reversal 2, dosage-sensitive 11.0
7 charcot-marie-tooth disease, type 1b 10.8
8 charcot-marie-tooth disease, type 4f 10.8
9 hemorrhagic fever 10.3
10 dengue hemorrhagic fever 10.3
11 intussusception 10.3 IL1B TNF
12 tau syndrome 10.3 IL1B TNF
13 oculomotor nerve paralysis 10.2 IL1B IL6
14 stocco dos santos syndrome 10.2 IL1B TNF
15 vps11-related autosomal recessive hypomyelinating leukodystrophy 10.2 IL6 TNF
16 common peroneal nerve lesion 10.2 IL1B IL6
17 cutaneous sclerosis 10.2 IL1RN IL6
18 hypotrichosis-lymphedema-telangiectasia-renal defect syndrome 10.2 IL1B TNF
19 dyslexia 5 10.2 IL6 TNF
20 mental retardation hypotonia skin hyperpigmentation 10.2 IL1B IL1RN THBD
21 aortic atherosclerosis 10.2 IL6 TNF
22 degenerative disc disease 10.2 IL6 TNF
23 shoulder impingement syndrome 10.2 IL1RN IL6
24 warthin tumor 10.2 IL1B IL1RN TNF
25 senile reticular retinal degeneration 10.2 IL1B IL1RN TNF
26 twin-to-twin transfusion syndrome 10.2 IL1B TNF
27 nasal cavity cancer 10.2 IL1B IL1RN TNF
28 childhood central nervous system mixed germ cell tumor 10.2 IL1B IL1RN TNF
29 retinal vascular occlusion 10.2 IL1B IL1RN TNF
30 anal paget's disease 10.2 IL1B IL6 TNF
31 unilateral multicystic dysplastic kidney 10.1 IL6 TNF
32 bipolar i disorder 10.1 IL1B IL6 TNF
33 muscular dystrophy-dystroglycanopathy , type a, 12 10.1 CCL2 IL1B
34 tinea capitis 10.1 IL1B IL6 TNF
35 measles 10.1 IL1B IL6 TNF
36 hypoparathyroidism-retardation-dysmorphism syndrome 10.1 IL1B IL6 TNF
37 mikulicz disease 10.1 IL1B IL6 TNF
38 acquired thrombocytopenia 10.1 IL1B IL6 TNF
39 rheumatoid factor-negative juvenile idiopathic arthritis without anti-nuclear antibodies 10.1 IL1B IL6 TNF
40 ectodermal dysplasia bartalos type 10.1 IL1B IL6 TNF
41 mineral metabolism disease 10.1 IL1B IL6 TNF
42 migraine with aura 10.1 IL1B IL6 TNF
43 neuropathy 10.1 IL1B IL6 TNF
44 splenic artery aneurysm 10.1 IL1B IL6 TNF
45 inappropriate adh syndrome 10.1 IL1B IL6 TNF
46 labyrinthitis 10.1 IL1B IL6 TNF
47 pancreas lymphoma 10.1 IL1B IL6 TNF
48 blepharochalasis 10.1 IL1B IL6 TNF
49 orthostatic proteinuria 10.1 IL1RN IL6 TNF
50 chordoid meningioma 10.1 IL1B IL6 TNF

Graphical network of the top 20 diseases related to Dengue Shock Syndrome:



Diseases related to Dengue Shock Syndrome

Symptoms & Phenotypes for Dengue Shock Syndrome

Symptoms:

12
  • easy bruising
  • blood spots
  • bleeding gums
  • nosebleeds

Drugs & Therapeutics for Dengue Shock Syndrome

Drugs for Dengue Shock Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 34)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Histamine Approved, Investigational Phase 4 75614-87-8, 51-45-6 774
2
Ketotifen Approved Phase 4 34580-14-8, 34580-13-7 3827
3 Anti-Allergic Agents Phase 4
4 Antipruritics Phase 4
5 Dermatologic Agents Phase 4
6 Histamine Antagonists Phase 4
7 Histamine H1 Antagonists Phase 4
8
Histamine Phosphate Phase 4 51-74-1 65513
9 Neurotransmitter Agents Phase 4
10
Ivermectin Approved, Vet_approved Phase 2, Phase 3 70288-86-7 6474909 46936176
11 Pharmaceutical Solutions Phase 3,Phase 2
12 Anti-Infective Agents Phase 2, Phase 3
13 Vaccines Phase 3,Phase 2,Phase 1
14 Heptavalent Pneumococcal Conjugate Vaccine Phase 3,Phase 2
15 Antiparasitic Agents Phase 2, Phase 3
16
Hydrocortisone Approved, Vet_approved Phase 2 50-23-7 5754 657311
17
Ribavirin Approved Phase 2 36791-04-5 37542
18
Neomycin Approved, Vet_approved Phase 1, Phase 2 1404-04-2 8378
19 Antimetabolites Phase 2
20 Antiviral Agents Phase 2
21 Cortisol succinate Phase 2
22 Hydrocortisone 17-butyrate 21-propionate Phase 2
23 Hydrocortisone acetate Phase 2
24 Antibodies Phase 1, Phase 2
25 Immunoglobulins Phase 1, Phase 2
26
Aluminum hydroxide Approved Phase 1 21645-51-2
27 Adjuvants, Immunologic Phase 1
28 Antacids Phase 1
29 Anti-Ulcer Agents Phase 1
30 Gastrointestinal Agents Phase 1
31 Aluminum sulfate Phase 1
32 gamma-Globulins
33 Immunoglobulins, Intravenous
34 Rho(D) Immune Globulin

Interventional clinical trials:

(show top 50) (show all 95)
id Name Status NCT ID Phase
1 Ketotifen as a Treatment for Vascular Leakage During Dengue Fever Recruiting NCT02673840 Phase 4
2 Effect of Hypertonic Sodium Lactate on sVCAM-1 Level as Surrogate Marker of Endothelial Capillary Leakage in Pediatric Dengue Shock Syndrome Patients (DSS) Unknown status NCT00966628 Phase 3
3 Study of a Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years in Malaysia Completed NCT01254422 Phase 3
4 Study of a Tetravalent Dengue Vaccine in Healthy Adults in Australia Completed NCT01134263 Phase 3
5 Study of a Booster Injection of Pentaxim™ Vaccine Administered With Dengue Vaccine in Healthy Toddlers Completed NCT01411241 Phase 3
6 Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers Completed NCT01436396 Phase 3
7 Efficacy and Safety of Ivermectin Against Dengue Infection Recruiting NCT02045069 Phase 2, Phase 3
8 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix® Recruiting NCT02979535 Phase 3
9 Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children Active, not recruiting NCT02747927 Phase 3
10 Study of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia Active, not recruiting NCT01373281 Phase 3
11 Study of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America Active, not recruiting NCT01374516 Phase 3
12 Study of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Adacel® in Healthy Subjects Not yet recruiting NCT02992418 Phase 3
13 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gardasil® Not yet recruiting NCT02993757 Phase 3
14 Chinese and Western Medicine Treatment of Fever Associated With Bleeding Symptoms Unknown status NCT01973855 Phase 2
15 Celgosivir as a Treatment Against Dengue Completed NCT01619969 Phase 1, Phase 2
16 Prospective Surveillance of Febrile Illness for Dengue-Endemic Areas in Asia Completed NCT01218906 Phase 2
17 Study of Febrile Illness for Dengue-Endemic Areas in Latin America Completed NCT01293331 Phase 1, Phase 2
18 A Study of Dengue Vaccine in Healthy Toddlers Aged 12 to 15 Months in the Philippines Completed NCT01064141 Phase 2
19 Immunogenicity and Safety of Three Formulations of Dengue Vaccines in Healthy Adults Aged 18 to 45 Years in the US Completed NCT00617344 Phase 2
20 Study of CYD Dengue Vaccine in Healthy Children and Adolescents in South America Completed NCT01187433 Phase 2
21 A Study of Two Doses of WRAIR Dengue Vaccine Administered Six Months Apart to Healthy Adults and Children Completed NCT00468858 Phase 2
22 Safety and Immunogenicity of Three Formulations of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) Completed NCT02193087 Phase 2
23 A Phase I/II Trial of a Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naïve Children Completed NCT00384670 Phase 1, Phase 2
24 Study of a Tetravalent Dengue Vaccine in Healthy Adult Subjects Aged 18 to 45 Years in India Completed NCT01550289 Phase 2
25 Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity After CYD Tetravalent Dengue Vaccine Completed NCT01943825 Phase 2
26 Safety and Immunogenicity of Formulations of Dengue Vaccines in Healthy Flavivirus-Naïve Adults Completed NCT00740155 Phase 2
27 Study of ChimeriVax™ Dengue Tetravalent Vaccine in Adult Subjects Completed NCT00730288 Phase 2
28 Study of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Subjects in Singapore Completed NCT00880893 Phase 2
29 Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Given With or Without Yellow Fever Vaccine Completed NCT01488890 Phase 2
30 Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Subjects Completed NCT00875524 Phase 2
31 Efficacy and Safety of Dengue Vaccine in Healthy Children Completed NCT00842530 Phase 2
32 Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years Completed NCT00788151 Phase 2
33 Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin America Completed NCT00993447 Phase 2
34 A Phase I/II Trial of Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naive Infants Completed NCT00322049 Phase 1, Phase 2
35 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Booster Injection in Subjects Who Previously Completed a 3-dose Schedule Recruiting NCT02824198 Phase 2
36 A Zika Virus DNA Vaccine in Healthy Adults and Adolescents Recruiting NCT03110770 Phase 2
37 Immunogenicity and Safety of 3-Dose and Booster Dose of Tetravalent Dengue Vaccine in Healthy Subjects 9 to 50 Years of Age Active, not recruiting NCT02628444 Phase 2
38 Study of a Booster Dose of a Tetravalent Dengue Vaccine in Subjects Who Previously Completed the 3-dose Schedule Active, not recruiting NCT02623725 Phase 2
39 Safety and Immunogenicity With Two Different Serotype 2 Potencies of Tetravalent Dengue Vaccine (TDV) in Adults in Singapore Active, not recruiting NCT02425098 Phase 2
40 Safety and Immunogenicity of Different Schedules of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Healthy Participants Active, not recruiting NCT02302066 Phase 2
41 Celgosivir or Modipafant as Treatment for Adult Participants With Uncomplicated Dengue Fever in Singapore Not yet recruiting NCT02569827 Phase 1, Phase 2
42 Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults Not yet recruiting NCT02741128 Phase 2
43 A Study of Balapiravir in Patients With Dengue Virus Infection Completed NCT01096576 Phase 1
44 Safety and Immunogenicity Study to Assess TDV, a Live Attenuated Tetravalent Vaccine for Prevention of Dengue Fever Completed NCT01224639 Phase 1
45 Safety of and Immune Response to Two Different Dengue Virus Vaccines in Individuals Previously Immunized Against Dengue Virus Completed NCT00458120 Phase 1
46 Safety of and Immune Response to a Dengue Virus Vaccine (rDEN1delta30) in Healthy Adults Completed NCT00089908 Phase 1
47 Safety of and Immune Response to a Dengue Virus Vaccine (rDEN2/4delta30[ME]) in Healthy Adults Completed NCT00094705 Phase 1
48 Safety of and Immune Response to a Dengue Virus Vaccine (rDEN4delta30-200,201) in Healthy Adults Completed NCT00270699 Phase 1
49 Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3delta30/31‐7164) in Healthy Adults Completed NCT00831012 Phase 1
50 Safety of and Immune Response to DEN4 Vaccine Component Candidate for Dengue Virus Completed NCT00919178 Phase 1

Search NIH Clinical Center for Dengue Shock Syndrome

Genetic Tests for Dengue Shock Syndrome

Anatomical Context for Dengue Shock Syndrome

MalaCards organs/tissues related to Dengue Shock Syndrome:

39
Skin, Heart, Liver, Endothelial, Bone, Bone Marrow, Whole Blood

Publications for Dengue Shock Syndrome

Articles related to Dengue Shock Syndrome:

(show top 50) (show all 132)
id Title Authors Year
1
In silico transcriptional regulation and functional analysis of dengue shock syndrome associated SNPs in PLCE1 and MICB genes. ( 27038471 )
2016
2
Clinical Characteristics and Risk Factors of Dengue Shock Syndrome in Children. ( 27455442 )
2016
3
Dengue shock syndrome. ( 28031845 )
2016
4
State-of-the-art monitoring in treatment of dengue shock syndrome: a case series. ( 27553703 )
2016
5
Delayed subdural hematoma after recovery from dengue shock syndrome. ( 27114678 )
2016
6
A Prognostic Model for Development of Profound Shock among Children Presenting with Dengue Shock Syndrome. ( 25946113 )
2015
7
Fatal invasive aspergillosis: a rare co-infection with an unexpected image presentation in a patient with dengue shock syndrome. ( 26072955 )
2015
8
Dengue haemorrhagic fever or dengue shock syndrome in children. ( 25860404 )
2015
9
Alpha tryptase allele of Tryptase 1 (TPSAB1) gene associated with Dengue Hemorrhagic Fever (DHF) and Dengue Shock Syndrome (DSS) in Vietnam and Philippines. ( 25797204 )
2015
10
Early resuscitation of Dengue Shock Syndrome in children with hyperosmolar sodium-lactate: a randomized single blind clinical trial of efficacy and safety. ( 25189175 )
2014
11
A replication study confirms the association of GWAS-identified SNPs at MICB and PLCE1 in Thai patients with dengue shock syndrome. ( 24884822 )
2014
12
Corticosteroids in the treatment of dengue shock syndrome. ( 24899817 )
2014
13
Dengue shock syndrome in an infant. ( 25073530 )
2014
14
Association of IL1B -31C/T and IL1RA variable number of an 86-bp tandem repeat with dengue shock syndrome in Thailand. ( 24446526 )
2014
15
Dengue Shock Syndrome or Dehydration? The importance of considering clinical severity when classifying patients with dengue. ( 24403543 )
2014
16
Differences in clinical features between children and adults with dengue hemorrhagic fever/dengue shock syndrome. ( 24437312 )
2013
17
Role of cognitive parameters in dengue hemorrhagic fever and dengue shock syndrome. ( 24305068 )
2013
18
Factors associated with dengue shock syndrome: a systematic review and meta-analysis. ( 24086778 )
2013
19
Possible cause of liver failure in patient with dengue shock syndrome. ( 23763890 )
2013
20
A patient with severe body aches without fever progressing to dengue shock syndrome. ( 24385064 )
2013
21
Serological characterization of dengue virus infections observed among dengue hemorrhagic fever/dengue shock syndrome cases in upper Myanmar. ( 23595687 )
2013
22
Clinical characteristics of dengue shock syndrome in Vietnamese children: a 10-year prospective study in a single hospital. ( 24046311 )
2013
23
Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection. ( 23471635 )
2013
24
Sympathetic dysfunction as a cause for hypotension in dengue shock syndrome. ( 23075741 )
2012
25
Splenic rupture mimicking dengue shock syndrome. ( 23025068 )
2012
26
Peritoneal dialysis in dengue shock syndrome may be detrimental. ( 22529870 )
2012
27
A fatal combo of dengue shock syndrome with acute subdural hematoma. ( 22406795 )
2012
28
Repeated dengue shock syndrome and 'dengue myocarditis' responding dramatically to a single dose of methyl prednisolone. ( 22521778 )
2012
29
Association of mast cell-derived VEGF and proteases in Dengue shock syndrome. ( 22363824 )
2012
30
A fatal case of bone marrow embolism of unknown cause masquerading clinically as dengue shock syndrome. ( 23455811 )
2012
31
Dengue shock syndrome with two atypical complications. ( 21842280 )
2012
32
Phenotypic characterization of patient dengue virus isolates in BALB/c mice differentiates dengue fever and dengue hemorrhagic fever from dengue shock syndrome. ( 21835036 )
2011
33
Dengue shock syndrome at the emergency room of Queen Sirikit National Institute of Child Health, Bangkok, Thailand. ( 22043755 )
2011
34
Characterization of dengue shock syndrome in pediatric patients in El Salvador. ( 21490492 )
2011
35
Infection-associated hemophagocytic syndrome among patients with dengue shock syndrome and invasive aspergillosis: a case series and review of the literature. ( 22299436 )
2011
36
Epidemiological factors associated with dengue shock syndrome and mortality in hospitalized dengue patients in Ho Chi Minh City, Vietnam. ( 21212214 )
2011
37
National guidelines for diagnosis and management of dengue fever/dengue haemorrhagic fever and dengue shock syndrome. ( 21888156 )
2011
38
Risk factors of dengue shock syndrome in children. ( 21367851 )
2011
39
Genome-wide association study identifies susceptibility loci for dengue shock syndrome at MICB and PLCE1. ( 22001756 )
2011
40
Phenotypic and genotypic characterization of dengue virus isolates differentiates dengue fever and dengue hemorrhagic fever from dengue shock syndrome. ( 21922323 )
2011
41
Should colloid boluses be prioritized over crystalloid boluses for the management of dengue shock syndrome in the presence of ascites and pleural effusions? ( 21356095 )
2011
42
Effect of a single dose of methyl prednisolone as rescue medication for patients who develop hypotensive dengue shock syndrome during the febrile phase: a retrospective observational study. ( 21530348 )
2011
43
Laboratory predictors of dengue shock syndrome during the febrile stage. ( 20578515 )
2010
44
Genome-wide expression profiling deciphers host responses altered during dengue shock syndrome and reveals the role of innate immunity in severe dengue. ( 20652028 )
2010
45
The early whole-blood transcriptional signature of dengue virus and features associated with progression to dengue shock syndrome in Vietnamese children and young adults. ( 20943967 )
2010
46
Dengue haemorrhagic fever or dengue shock syndrome in children. ( 19445771 )
2009
47
Risk factors associated with development of dengue haemorrhagic fever or dengue shock syndrome in adults in Hospital Tengku Ampuan Afzan Kuantan. ( 20954558 )
2009
48
Persistent thrombocytopenia following dengue shock syndrome. ( 19381512 )
2009
49
Acute renal failure in a patient with severe malaria and dengue shock syndrome. ( 19000545 )
2008
50
Clinical, laboratory and radiological parameters in children with dengue fever and predictive factors for dengue shock syndrome. ( 17965098 )
2008

Variations for Dengue Shock Syndrome

Expression for Dengue Shock Syndrome

Search GEO for disease gene expression data for Dengue Shock Syndrome.

Pathways for Dengue Shock Syndrome

Pathways related to Dengue Shock Syndrome according to GeneCards Suite gene sharing:

(show all 44)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.27 CCL2 HLA-A HLA-DRB1 IL1B IL1RN IL6
2
Show member pathways
12.9 CCL2 IL1B IL1RN IL6 TNF
3
Show member pathways
12.79 HLA-A HLA-DRB1 IL1B IL6 TNF
4
Show member pathways
12.65 CCL2 HLA-A HLA-DRB1 IL1B IL6 TNF
5
Show member pathways
12.52 HLA-DRB1 IL1B IL6 TNF
6
Show member pathways
12.51 CCL2 IL1B IL6 TNF
7 12.46 CCL2 IL1B IL1RN TNF
8 12.36 HLA-A HLA-DRB1 IL6 TNF
9
Show member pathways
12.28 CCL2 IL1B IL6 TNF
10
Show member pathways
12.27 CCL2 IL1B IL6 TNF
11 12.18 HLA-DRB1 IL1B IL6 TNF
12 12.12 IL1B IL1RN IL6 TNF
13
Show member pathways
12.06 HLA-A IL1B IL6 TNF
14 12.02 CCL2 IL1B THBD TNF
15 11.92 CCL2 IL1B IL6 TNF
16
Show member pathways
11.91 HLA-A HLA-DRB1 IL1B
17
Show member pathways
11.88 IL1B IL6 TNF
18 11.88 CCL2 IL1B IL6 TNF
19 11.84 CCL2 IL1B IL6 TNF
20 11.82 IL1B IL6 TNF
21 11.78 HLA-DRB1 IL1B IL6 TNF
22 11.72 IL1B IL6 TNF
23
Show member pathways
11.62 IL1B IL6 TNF
24 11.61 IL1B IL6 THBD TNF
25 11.61 CCL2 HLA-DRB1 IL1B IL6 TNF
26 11.55 IL1B IL6 TNF
27 11.49 CCL2 IL1B TNF
28 11.44 IL1B IL6 TNF
29 11.36 CCL2 IL1B IL6 TNF
30 11.35 CCL2 CMA1 IL1B IL6 TNF
31 11.32 IL1B IL6 TNF
32 11.31 IL1B IL6 TNF
33 11.29 CCL2 IL6 THBD
34 11.25 IL1B IL6 TNF
35 11.23 IL1B IL6 TNF
36 11.1 HLA-DRB1 IL1B IL6 TNF
37 11.1 CCL2 IL1B IL6 PLCE1 THBD TNF
38 11.04 IL1B TNF
39 11.04 CCL2 IL1B IL1RN IL6 TNF
40 11.03 IL6 TNF
41 11.03 CCL2 IL1B IL6 PLCE1 TNF
42 10.97 IL6 TNF
43 10.86 IL1B IL6
44 10.84 CCL2 IL1B TNF

GO Terms for Dengue Shock Syndrome

Cellular components related to Dengue Shock Syndrome according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.43 CCL2 IL1B IL1RN IL6 THBD TNF
2 cell surface GO:0009986 9.02 HLA-A HLA-DRB1 MICB THBD TNF

Biological processes related to Dengue Shock Syndrome according to GeneCards Suite gene sharing:

(show all 32)
id Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 9.83 CCL2 IL1B IL6
2 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.82 IL1B IL6 TNF
3 cellular response to lipopolysaccharide GO:0071222 9.82 CCL2 IL6 TNF
4 response to lipopolysaccharide GO:0032496 9.81 CCL2 IL1B IL6 THBD
5 activation of MAPK activity GO:0000187 9.8 IL1B PLCE1 TNF
6 positive regulation of sequence-specific DNA binding transcription factor activity GO:0051091 9.79 IL1B IL6 TNF
7 inflammatory response GO:0006954 9.77 CCL2 IL1B IL1RN IL6 TNF
8 cellular response to organic cyclic compound GO:0071407 9.76 CCL2 IL1B TNF
9 humoral immune response GO:0006959 9.73 CCL2 IL6 TNF
10 antigen processing and presentation GO:0019882 9.72 HLA-A HLA-DRB1 MICB
11 response to heat GO:0009408 9.67 CCL2 IL6 MICB
12 positive regulation of NF-kappaB import into nucleus GO:0042346 9.65 IL1B TNF
13 negative regulation of lipid catabolic process GO:0050995 9.64 IL1B TNF
14 positive regulation of chemokine production GO:0032722 9.63 IL6 TNF
15 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.63 IL1B TNF
16 regulation of I-kappaB kinase/NF-kappaB signaling GO:0043122 9.62 IL1B TNF
17 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.61 IL1B TNF
18 positive regulation of interleukin-6 production GO:0032755 9.61 IL1B IL6 TNF
19 positive regulation of chemokine biosynthetic process GO:0045080 9.6 IL1B TNF
20 negative regulation of lipid storage GO:0010888 9.59 IL6 TNF
21 regulation of establishment of endothelial barrier GO:1903140 9.58 IL1B TNF
22 positive regulation of nitric oxide biosynthetic process GO:0045429 9.58 IL1B IL6 TNF
23 epithelial cell proliferation involved in salivary gland morphogenesis GO:0060664 9.57 IL6 TNF
24 regulation of vascular endothelial growth factor production GO:0010574 9.54 CCL2 IL6
25 positive regulation of fever generation GO:0031622 9.52 IL1B TNF
26 sequestering of triglyceride GO:0030730 9.48 IL1B TNF
27 negative regulation of interleukin-1-mediated signaling pathway GO:2000660 9.46 IL1RN IL6
28 protein kinase B signaling GO:0043491 9.43 CCL2 IL1B TNF
29 lipopolysaccharide-mediated signaling pathway GO:0031663 9.33 CCL2 IL1B TNF
30 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.32 IL1B TNF
31 response to glucocorticoid GO:0051384 9.26 CCL2 IL1RN IL6 TNF
32 immune response GO:0006955 9.17 CCL2 HLA-A HLA-DRB1 IL1B IL1RN IL6

Molecular functions related to Dengue Shock Syndrome according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.02 CCL2 IL1B IL1RN IL6 TNF
2 interleukin-1 receptor binding GO:0005149 8.96 IL1B IL1RN

Sources for Dengue Shock Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....